TABLE 1

Demographics, diagnosis, and antimicrobial therapy for study subjects (n = 64)

CharacteristicaNo. of subjects (%)
or parameter value
Age (yr)
    Mean27.0
    Range15 − 58
    SD9.6
Sex
    Male60 (93.8)
    Female4 (6.3)
Race
    Black59 (92.2)
    White5 (7.8)
Treatment regimen
    Azithromycin (1 g) + ceftriaxone (250 mg)34
    Azithromycin (1 g) + ceftriaxone (250 mg) + metronidazole (2 g)23 (35.9)
    Azithromycin (1 g) + ceftriaxone (250 mg) + ciprofloxacin
  (500 mg BID for 7 days)
1 (1.6)
    Ciprofloxacin (500 mg BID for 14 days)1 (1.6)
    Cephalexin 500 mg BID for 7 daysb1 (1.6)
    Azithromycin (1 g) + TMP-SMX1 (1.6)
    Metronidazole (2 g) onlyc1 (1.6)
    Treatment information not available2 (1.6)
Neisseria gonorrhoeae NAAT test result
    Positive for N. gonorrhoeae (of tested subjects)59 (98.3)
    Negative for N. gonorrhoeae (of tested subjects)0 (0.0)
    Indeterminate (of tested subjects)1 (1.7)
    NAAT not performed (of total subjects)4 (6.3)
Concurrent STI
    None documented37 (57.8)
    Chlamydia trachomatis18 (28.1)
    Trichomonas vaginalis2 (3.1)
    HIV2 (3.1)
    HCV1 (1.6)
    Not screened or data not available4 (6.3)
Specimen source
    Urine sample58 (90.6)
    Genital swab4 (6.3)
    Wound swab1 (1.6)
    Ocular swab1 (1.6)
Culture method
    Kiestra TLA52 (81.3)
    Conventional microbiology workflow12 (18.8)
  • a Abbreviations: BID, twice a day; TMP-SMX, trimethoprim-sulfamethoxazole.

  • b Complicated by pyelonephritis.

  • c This patient, treated with metronidazole only, presented 2 weeks later and was treated with azithromycin (1 g) plus ceftriaxone (250 mg).